You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Pharming Group belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same ...

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly results. The firm notes 2024 revenue of $297M came ...

That makes leniolisib important for Pharming's future growth prospects while it works on new uses for Ruconest in areas like acute kidney injury and a gene therapy for HAE partnered with Orchard ...

Explore Pharming stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PHAR. European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study ...

Hereditary angioedema is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of ...

Across the recent three months, 4 analysts have shared their insights on Pharming (NASDAQ:PHAR), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Pharming's patient-finding efforts are continuing ... A significant challenge in diagnosing APDS patients occurs when a patient's genetic test result shows a VUS, or a variant of unknown significance.

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...